Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: Insmed Netherlands B.V., Stadsplateau 7, 3521 AZ Utrecht, Netherlands
Brinsupri 25 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Grey, approximately 9 mm diameter round tablet debossed with "25" on one side and "BRE" on the other side. |
Each film-coated tablet contains 25 mg of brensocatib (as monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Brensocatib is a competitive and reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Brensocatib reduces the activity of NSPs implicated in the pathogenesis of bronchiectasis, including neutrophil elastase, cathepsin G and proteinase 3. |
| List of Excipients |
|---|
|
Tablet core: Cellulose, microcrystalline Film-coating: Poly(vinyl alcohol) |
PVC/PCTFE aluminium foil blister card containing 14 film-coated tablets.
Pack size of 28 tablets (2 blister cards of 14 tablets each) in a carton.
Insmed Netherlands B.V., Stadsplateau 7, 3521 AZ Utrecht, Netherlands
EU/1/25/1995/001
| Drug | Countries | |
|---|---|---|
| BRINSUPRI | Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.